No Data
No Data
Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Mizuho Securities Downgrades Intra-Cellular Therapies(ITCI.US) to Hold Rating, Cuts Target Price to $132
Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM) and Merck & Company (MRK)
Benson_188 : moomoo 2025 Spring Festival red envelope! Test your luck and win up to 888* >> https://j.moomoo.com/023qve
CNNT : Enjoy reading about these stocks that are not on hype-seeking investors' radar. TQ.